Decent Early Indications for LGND

Just a quick note that GlaxoSmithKline released results yesterday — for those who are interested in Ligand, which I own and have written about several times over the past year, the Promacta news looked pretty good. Despite Lemelson’s short argument that Promacta is a rapidly declining and worthless drug because of better Hepatitis C treatment […]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.